Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
NCT07675967
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers. The study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer (Diagnosis)
- Osteochondroma
- Spitz Nevus
- Solid Cancers
- Breast Cancer
- Gastric (Stomach) Cancer
- Colorectal (Colon or Rectal) Cancer
- Sarcoma
- Ovarian Adenocarcinoma
- Uterine Adenocarcinoma
- Endometrial Adenocarcinoma
- Esophageal Adenocarcinoma
- Head and Neck Cancer
- Therapy-Related Acute Myeloid Leukemia
- Therapy-Related MDS
- Clonal Hematopoiesis of Indeterminate Potential (CHIP)
- Clonal Cytopenia of Undetermined Significance
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- June 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.